Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEC255 in advanced solid tumors with KRAS p.G12C mutation
NCT05768321Phase 1Unknown
- Sponsor
- GenEros BioPharma Ltd.
- Start
- Nov 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GEC255 in solid tumor (advanced stage), sponsored by GenEros BioPharma Ltd. Primary endpoints: Dose limiting toxicities at 28 days, Recommended Phase 2 Dose at 24 months and 4 more. Status: unknown.
02
Drugs
GEC255
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05768321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768321.